×
Hero Background

Gitelman Syndrome Companies

ID: MRFR/LS/3866-HCR
90 Pages
Kinjoll Dey
October 2025

Gitelman syndrome is a rare genetic disorder that affects the kidneys, specifically the renal tubules. It is characterized by low levels of potassium and magnesium in the blood, as well as other electrolyte imbalances. Companies involved in healthcare and pharmaceuticals may conduct research, develop treatments, or provide supportive therapies for individuals with Gitelman syndrome.

Share:
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

Gitelman Syndrome Market Research Report – Global Forecast till 2035 Infographic
Summary Table of Contents Segmentation Download PDF

Top Industry Leaders in the Gitelman Syndrome Market

Gitelman Syndrome Market

 


Latest Gitelman Syndrome Companies Updates:


BioMarin Pharmaceutical releases promising early data from a Phase 2 clinical trial of BMN-351, a novel investigational therapy aiming to address the underlying cause of Gitelman Syndrome by correcting the defective sodium chloride cotransporter.


Horizon Therapeutics receives FDA approval for Krystexxa® (burokalifex) extended-release tablets for treating hypokalemia (low potassium levels), a common symptom in Gitelman Syndrome.


AstraZeneca partners with academic institutions to conduct research on potential gene therapy approaches for Gitelman Syndrome, offering a future possibility for a one-time curative treatment.


The Gitelman Syndrome Foundation collaborates with pharmaceutical companies and research institutions to accelerate clinical trials and advance Gitelman Syndrome research.


List of Gitelman Syndrome Key companies in the market:



  • Pfizer Inc. (U.S.)

  • Hisoar (China)

  • Taj Pharmaceuticals Ltd. (India)

  • Merck & Co., Inc. (U.S.)

  • Xinhua Pharm (China)

  • BIOCAUSE Inc. (China)

  • Thermo Fisher Scientific Inc. (U.S.)

  • Bio-Rad Laboratories, Inc. (U.S.)

  • F. Hoffmann-La Roche Ltd (Switzerland)

  • QIAGEN (Germany)